Loading company…
ToxoTech develops botulinum neurotoxin therapies for neuromuscular and neurological disorders.
ToxoTech develops engineered botulinum neurotoxin therapies designed to target neurons for treatment of neuromuscular and neurological disorders. Founded in 2020 by CEO Geoffrey Masuyer, the company is based in Stockholm, Sweden. In January 2026, it raised venture funding from Industrifonden to support development of its platform.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in